A new Nature Biomedical Engineering study reported targeted lipid nanoparticles (LNPs) enabling in vivo gene editing in human blood stem cells without using viral vectors. The approach aims to deliver editing machinery directly to hematopoietic stem cells inside the body, addressing a long-standing bottleneck in clinically scalable editing methods. By focusing on non-viral delivery, the platform could reduce some of the complexity and constraints associated with viral systems, while maintaining cell targeting appropriate for long-term engraftment. For translation teams, the work adds another delivery route in the push toward direct-from-patient, in vivo genome editing programs.